Abstract:Abstract Long-term remission for acute myeloid leukemia (AML) is still not achieved for the majority of patients and consequently there is a need for new treatments to consolidate current therapy. A promising approach is to augment the anti-tumor immune response in these patients; however most cancers do not activate immune effector cells because they express immunosuppressive ligands. Previously we showed that CD200 overexpression on AML blasts suppresses memory CD4+ and CD8+ T cell effector function through engagement with CD200 receptor (CD200R) on these cells. Blocking CD200:CD200R, however, only partially restored T cell activity, suggesting that alternative immunosuppressive mechanisms were involved. Recently, promising clinical outcomes have been reported for melanoma and non-small cell lung cancer using humanized antibodies targeting another immunosuppressive receptor, PD-1, and we therefore investigated whether this could be contributing to the immunosuppression of T cell effector responses in CD200hi AML patients. Initially, we investigated whether CD200 and the immunosuppressive ligand for PD-1, PD1-L1, were co-expressed in AML blasts at diagnosis. Affymetrix gene expression data from 158 AML blasts showed that AML patients in the upper quartile for CD200 expression (CD200hi) had 10-fold higher levels of PD1-L1 expression compared to CD200lo (lower quartile) patients. Analysis of CD200 and PD1-L1 protein expression on AML blast cells confirmed this association at the protein level (r2 = 0.49; p<0.01). The co-expression of CD200 and PD1-L1 on patient AML blast cells, suggested that they cooperated in immunosuppression. In support of this, we found that the CD200 and PD1-L1 cognate co-receptors (CD200R and PD-1 respectively) were present on CD4+ and CD8+ T cells from AML patients. Further characterization of PD-1+ T cells showed that the mean frequency of PD-1+ early differentiated T cells (CD57- CD28+) was increased for CD200hi AML patients CD4+ (19% ± 3 vs 13% ± 3; p<0.05) and CD8+ T cells (21% ± 3 vs 11% ± 2; p<0.05). We also found that the mean frequency of late differentiated CD8+ T cells that have poor anti-tumor function (CD57+ CD28- PD-1+) was almost twice that for CD200hi patients compared with CD200lo (38% ± 6 vs 21% ± 9 respectively; p<0.05). Expansion of these cells was also associated with a decreased CD4:CD8 ratio in these patients (2.1 ± 0.5 vs 3.7 ± 1 for CD200hi and CD200lo respectively; p<0.01). . These findings show for the first time a link between CD200 expression level on AML blast cells and the frequency of PD-1+ late differentiated CD8+ T cells. To directly test whether engagement of CD200 with CD200R was capable of mediating PD-1 up-regulation on CD8+ T cells, we co-cultured a CD8+ CD200R+ T cell clone (7E7) either with K562 cells stably overexpressing CD200 or K562 empty vector controls (negative for CD200). Co-culture with CD200+ cells, significantly increased the frequency of PD-1+ T cells (26% ± 3 vs 17% ± 4; p<0.05) and this was antagonized by CD200 blocking antibody (26% ± 3 vs 21% ± 3; p 50%) reduction in the frequency of activated 7E7 T cells; however, when both CD200 and PD1-L1 were co-expressed, T cell activation was almost ablated (~90% reduction; p<0.01). Moreover, the strength of the TNFα response was also reduced in co-culture assays where either CD200 or PD1-L1 were present, indicating a direct effect at the level of CD8+ T cell function (2.8 ± 0.5 vs 1.7 ± 0.5; p<0.05). These data demonstrate that CD200:CD200R and PD1-L1:PD-1 engagement on T cells can act in tandem to augment immunosuppression of CD8+ T cells. In summary, we show for the first time that the immunosuppressive molecules, CD200 and PD1-L1 appear to be co-regulated on AML blasts and that these can act in combination to profoundly suppress T cell activation. Further, we show that CD200:CD200R engagement induces PD-1+ CD8+ T cells. Taken together we propose a novel CD200/PD1-L1 immunotherapeutic synapse in AML which should be targeted by combining CD200:CD200R and PD1-L1:PD-1 blockade in immunotherapy of AML. Disclosures No relevant conflicts of interest to declare.

CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia

Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia

Dysregulation of Immune Regulators in AML Bone Marrow Promotes Dysfunction of CD8 + T Cells

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion

CD200 and PD1-L1 in AML Are Associated with Expanded PD-1+ Late Differentiated CD8+ T Cells and a Decreased CD4:CD8 Ratio: a New Link Between Distinct Immunosuppressive Pathways

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

Bone Marrow GZMK +IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

744 Single Cell Profiling of Acute Myeloid Leukemia (AML) and Its Microenvironment Reveals a CD8 Continuum and Adaptable T Cell Plasticity in Response to PD-1 Blockade-Based Therapy

Abstract PR003: Single-cell Profiling of Acute Myeloid Leukemia (AML) and Its Microenvironment Reveals a CD8 Continuum and Adaptable T Cell Plasticity in Response to PD-1 Blockade-Based Therapy

Extraordinarily Elevated CD33 Expression in CD56+CD3– Cells in the Bone Marrow of a Patient with Relapsed Acute Myeloid Leukemia: a Case Report

Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review

Abstract 187: Macrophage instead of leukemia cell expressed PD-L1 drives T cell exhaustion and immune evasion of BCRABL1 chronic myeloid leukemia

Lactate acid promotes PD-1 + Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia

Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy